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I
n recent years, researchers have recognized the tremendous
potential of protein microarrays. Over a decade ago, the DNA
microarray revolutionized the way in which biologists analyze
gene expression.
1-3 DNA arrays have been successfully imple-
mented in a variety of applications ranging from genome-wide
screens for chromosomal abnormalities to the identiﬁcation of
coregulated gene networks during embryonic development.
However, while gene function studies that utilize mRNA expres-
sion levels are somewhat informative, they often do not corre-
spond well with the abundance of protein levels in the cell.
4
Accordingly,manyresearchershaveadoptedproteinmicroarrays
to directly investigate protein expression patterns and protein
function.
5,6 Protein microarrays make it possible to study the
expression of the entire proteome (or a subset of the proteome)
in a multiplex format. Although this advance addresses a crucial
limitation,protein microarrayshaveenjoyedlimitedsuccessthus
far compared to DNA microarrays due to the highly complex
nature of the antibody-antigen interaction.
4 Here we introduce
a novel nanosensor-based technique that can simplify and enhance
thereliability ofproteinarray-basedanalysis,allowingtheﬁeldto
unlock the true potential of protein microarrays.
The complexity of protein interaction presents a number of
signiﬁcant challenges. Unlike the predictable sequence-speciﬁc
hybridization chemistry of nucleic acids, proteins exhibit incred-
ible diversity in their functional groups, aﬃnities, and secondary
and tertiary structure. In addition, after translation, proteins
typically undergo multimerization and post-translational mod-
iﬁcation, such as acetylation, glycosylation, and phosphorylation,
making the protein structure even more diverse. As a result,
protein replication or ampliﬁcation is not possible with current
tools, limiting the sensitivity of protein microarrays. Further-
more,antibodiesonlybindtoasmallportionofthetargetprotein,
known as the epitope. Given the incredibly complex structure of
eachprotein,antibodiesinahighdensityproteinarrayoftenbind
aberrantly to epitopes with identical or similar structure in oﬀ-
target proteins,
7,8 resulting in nonspeciﬁc cross-reactive signals.
(In this paper, we refer to cross-reactions and aberrant binding
events synonymously, since both are undesired or unexpected
binding events beyond the speciﬁc binding between a pair of
targeted protein and antibody.) This cross-reactivity problem is
exacerbated when researchers employ polyclonal antibodies,
which are mixtures of antibodies that bind to multiple diﬀerent
epitopes on a particular protein. Not surprisingly, the literature
is ﬁlled with examples of such cross-reactive monoclonal and
polyclonal antibodies that have necessitated reassessment of
data or even retraction of experimental ﬁndings.
9 The constant
push to increase the density of protein arrays will only further
compoundthisproblem.However,nouniversally accepted method
for assessing antibody cross-reactivity exists.
9
To address these concerns, we have designed a simple and sen-
sitive nanosensor-based immunoassay capable of rapidly characteriz-
ing antibody cross-reactivity. This assay employs high density arrays
of giant magnetoresistive (GMR) nanosensors
10,11 and magnetic
nanotags,asdiagrammedinFigure1.Furthermore,wehavedesigned
thisassayasaone-step,wash-freeprocessemployingthesite-speciﬁc
autoassembly characteristics of macromolecular complexes.
Our innovation relies on magetoresistance, a property of
GMR sensors rooted in quantum mechanics, by which a change
intheexternalmagneticﬁeldinducesaspin-dependentchangein
theelectricalresistanceofthedevice.Inparticular,spinvalvetype
GMR nanosensors have high linearity and low noise, making
them ideal for quantitatively detecting magnetic nanotags.
12,13
Prior work has demonstrated that by implementing a traditional
sandwich assay using magnetic nanotags, GMR spin valve bio-
sensors are capable of multiplexed protein detection at femto-
molar to attomolar sensitivities.
14,15
The traditional sandwich assay utilized in our prior work has
been completely redesigned here. In this report, we demonstrate
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ABSTRACT: We report an autoassembly protein array capable of rapidly screening
for aberrant antibody-antigen binding events. Our technique combines magnetic
nanoparticle technology with proximity-based, magnetically responsive nanosensors
for rapid (under 15 min) and high-density screening of antibody cross-reactivity at
sensitivities down to 50 fM in a homogeneous assay. This method will enable the
identiﬁcationoftheprecisecauseofaberrantorcross-reactivebindingeventsinaneasy-
to-use, rapid, and high-throughput manner.
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a novel autoassembly immunoassay by leveraging the proximity-
based detection capabilities and unique magnetic properties of
our GMR-based biosensor system (elaborated in Supporting
Information, Figure S1). As described below, we allow the anti-
body and magnetic nanoparticle to bind on the surface of the
sensorallinthesamesolution,removingthewashstepsrequired
fortraditionalsandwichassays(Figure1).Thus,bytakingadvan-
tage of what we term autoassembly, this assay requires only
minimal human intervention and requires no laboratory training
to perform. The assay works as follows. Arrays of GMR sensors
areprefunctionalizedwithapanelofcaptureantibodiestargeting
the proteins of interest. Upon sample incubation in the reaction
well, the biomolecules of interest are selectively captured by
antibodies that have been immobilized directly over GMR sensors
(alternatively, the target proteins can be directly immobilized
on the sensor surface, though this may lead to undesirable con-
formational changes in protein structure). To illustrate, we employ
piezoelectric robotic spotter technology (Scienion sciFlexarrayer,
BioDot) to spot 350 picoliter droplets of capture antibody
onto individually addressable GMR nanosensors in the array
(Figure 1b insert). The user then adds a solution of magnetic
nanotags labeled with streptavidin to the reaction well. At this
point, no reaction takes place because complementary reaction
chemistrybetweenthecapturedantigenandmagneticnanotagis
not yet present in the well (Figure 1a). Detection antibodies
labeled with biotin are sequentially introduced. Upon introduc-
tion, each detection antibody diﬀuses throughout the reaction
well and acts to link the magnetic nanotags to surface-immobilized
analyte,creatingasignalintheunderlyingGMRsensor(Figure1b).
In this way, the cross-reactivity of each successive antibody in a
panelcanbeassessedwithonlyoneadditionalwash-freestep.No
washingstepsarerequiredbetweensequentialadditionsofdetec-
tion antibody or after adding magnetic nanotag solution. The assay
isruninanopen-wellformat,removingtheneedforcomplexmicro-
ﬂuidic plumbing or external pneumatic pressure controllers.
In a demonstration experiment, we monitored GMR signal in
real-time toshow thataddition of sampleandmagneticnanotags
without detection antibody produces no signiﬁcant rise in the
GMR signal. However, once the detection antibody is intro-
duced,themagneticnanotags congregate over thesensorsurface
in high enough density to be detected by the underlying GMR
sensor (Figure 2a). As noted above, each sensor in the array is
individually addressable and monitored in real-time. Therefore,
upon sequential addition of diﬀerent detection antibodies at
uniquetimepoints,itispossibletoisolatethesignalandpotential
for cross-reaction from each antibody addition—an important
advance that is unique to our new method.
Currently, ﬂuorescent or colorimetric detection is implemen-
ted when performing protein microarrays. These technologies
typically have a detection limit of ∼1 pM, 2 orders of linear
dynamic range, and assay times of approximately half a day.
9
While alternative methods such as mass-spectrometric antigen
identiﬁcation and two-dimensoinal polyacrylamide gel electro-
phoresis have been demonstrated, their protocols are technically
challenging, expensive, and even more time-consuming. In addi-
tion, although the Western blot has been used in the past to
examine cross-reactivity, this technique has the potential to
misrepresent antibody speciﬁcity due to the highly denaturing
conditions of the assay.
9 Furthermore, while cross-reaction may
be apparent, Westerns cannot identify the source of the aberrant
binding event, providing minimal information for future experi-
ments. In short, all of these existing solutions possess severe
limitations that have prevented protein microarrays from realiz-
ing their potential.
In contrast, the autoassembly immunoassay presented here is
simple to implement because it lacks tedious washing steps,
Figure 1. Schematic representation of the autoassembly immunoassay where each square represents a 100 μm  100 μm GMR nanosensor and each
color represents a unique target antibody and antigen. (a) After immobilizing unique capture antibodies over a unique, individually addressable sensor
andincubatingwiththeproteinofinterest,themagneticnanotagsareaddedinsolutionabovethesensor.Sincethereisnochemistrytolinkthemagnetic
nanotagstothecapturedantigen,nosignalisdetectedbytheunderlyingsensor.(b)Aseachofthedetectionantibodiesaresequentiallyintroduced,they
arecapableoflinkingthestreptavidinlabeledmagneticnanotagstothecapturedanalytes.Inthepresenceofcapturedanalyte,themagneticnanotagswill
congregate over the corresponding GMR sensors in high enough concentration to be detected. Insert: optical microscopy of a section of the array of
nanosensors. Each square in the array is one sensor and each circle is a nanoliter droplet of capture antibody uniquely functionalized over the sensor
surface.2581 dx.doi.org/10.1021/nl1026056 |Nano Lett. 2011, 11, 2579–2583
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utilizes simple salt buﬀers that do not denature the antibodies or
proteins, and achieves at least an order of magnitude higher
sensitivity in less than 15 min. Indeed, by employing magnetic
sensing rather than optical detection, we can achieve detection
down to 50 fM in a 25 μL sample (Figure 2b). For the sake of
completeness, we note that the linear dynamic range and lower
limit of detection using the autoassembly immunoassay on our
GMR sensor array are not as broad as in the standard sandwich
immunoassay on our GMR sensor array.
15
To illustrate the application to the identiﬁcation of aberrant
antibodybindingevents,weperformedatrialscreenforantibody
cross-reactivity. To begin, we examined the cross-reactivity of an
antiepidermal growth factor receptor (EGFR) antibody to a
panelof20uniquetargetproteins.Wespottedantibodiestoeach
of the 20 target proteins on the sensor, followed by addition of
the target proteins themselves, which were thereby immobilized
to the surfaces over their respective sensors. For the experiment,
we added magnetic nanotags, followed by the addition of bio-
tinylated anti-EGFR detection antibody. While the majority of
proteinsrevealednodetectablecross-reaction, theassaywasable
tohighlighttwosensorsinadditiontoEGFRthatwereboundby
the anti-EGFR antibody; the epithelial cell adhesion molecule
(EpCAM) andhuman trophoblast cell-surfaceantigen (TROP2,
also termed GA733-1, M1S1, or EGP-1) (Figure 3a,b). Control
experiments in which Trop2 and EpCAM were absent, and in
which EGFR protein was absent, each revealed no cross-reactivity,
conﬁrming that the cross-reaction was due to detection anti-
body-antigen interaction and not due to detection antibody
bindingtocaptureantibody(SupportingInformation,FiguresS2
and S3). Similarly, when anti-Trop2 detection antibody was
introduced instead of anti-EGFR antibody, we observed cross-
reactive binding between anti-Trop2 antibody over the sensor
functionalized with anti-EGFR antibody (Supporting Information,
Figure S4).
From a survey of the literature, it is not surprising that these
twoadditionalproteinsexhibitedcross-reaction,asbothEpCAM
and Trop2 contain EGF-like domains.
16 Therefore, EGFR protein,
whichiscapableofbindingEGF-likedomains,mostlikelybound
to the EGF-like domains on captured Trop2 and EpCAM protein.
Consequently, a more complex sandwich structure was ﬁrst formed
over the anti-Trop2 antibody-coated sensor on which Trop2
protein was captured. Subsequently, the EGF-like domain on
Trop2wasboundbyEGFR, andﬁnally,EGFRwasboundbythe
anti-EGFR detection antibody (Figure 3a). While the aberrant
binding events we present here can be explained by the structure
of the reacting proteins, the majority of cross-reactive binding
events are not so easily predicted. In many situations, antibodies
may recognize a nonlinear conformational protein epitope that
cannot be predicted via sequence homology.
17-20
When performing a traditional protein microarray, detec-
tion antibodies are added simultaneously (in a cocktail) instead
ofsequentially(i.e.,onlyonedetectionantibodyatatime).However,
Figure 2. (a)Real-time monitoringofsensorsduringautoassemblyimmunoassay. Additionofthesampleandmagnetic nanotagscontributenegligible
signal (upon addition of the magnetic nanotags, there is a very small signal rise due to detection of magnetic nanotags in solution above the sensor).
However, once the detection antibody is introduced, the magnetic nanotags are clearly measurable on sensors functionalized with the appropriate
capture antibody and antigen. The negative control sensors, coated with a noncomplementary antibody, anti-insulin antibody, remain ﬂat, indicating
negligible nonspeciﬁc binding. The y-axis units are the change in magnetoresistance normalized to the initial magnetoresistance presented in parts per
million (ppm). (b) Full scale graph of anti-CEA detection antibody binding selectively to captured CEA protein when performing the autoassembly
immunoassay.(c)SuperimposedcalibrationcurvescomparingtheautoassemblyassaytothetraditionalsandwichassayusingGMRnanosensorsinboth
assays.AlthoughthelineardynamicrangeisnotquiteasgoodasthetraditionalimmunoassayusingGMRbiosensors,theautoassemblyassayisstillquite
sensitive with a lower limit of around 50 fM.2582 dx.doi.org/10.1021/nl1026056 |Nano Lett. 2011, 11, 2579–2583
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if the prior experiment had been performed like a traditional
protein microarray sandwich assay, using a cocktail of detection
antibodies to all 20 proteins, the origin of the signals from the
sensors immobilized with Trop2 capture antibody or the sensors
immobilized with EpCAM capture antibody would certainly be
ambiguous and potentially misleading. Distinguishing the
amountof signalgenerated over the Trop2 sensor by anti-Trop2
detectionantibodybindingtoTrop2proteinfromtheamountof
signal generated by anti-EGFR detection antibody binding to
EGFRcapturedontheEGF-likedomainofTrop2proteinwould
be impossible. Indeed, every antibody that is currently in use in
a protein microarray with unrecognized cross-reactivity would
present the same concern.
Using our autoassembly immunoassay, we can address this
issue by simply introducing detection antibody sequentially in
timetoisolateeachdetectionantibodythatisaberrantlybinding.
Doing sequential addition with traditional protein microarrays
wouldbeprohibitivelytime-consuming, sincethesetoolsrequire
lengthy incubation times and several washing steps for each anti-
body. However, using the autoassembly immunoassay presented
here, we can simply and rapidly screen through a panel of poten-
tially cross-reactive antibodies.
By sequentially adding each antibody of interest to the GMR
protein array at unique time points, it is possible to rapidly
identify the source of aberrant binding events in real-time. To
illustrate, in Figure 3c we ﬁrst added anti-EGFR antibody to the
reaction well. Not only did the anti-EGFR antibody bind to the
EGFR protein, but it also bound over the anti-Trop2 protein, as
described above. Upon addition of the anti-CEA detection anti-
body, however, no such cross-reaction was observed, and only
the sensor with anti-CEA capture antibody exhibited a binding
curve. Signal over the noncomplementary antibody and BSA
control sensors remained ﬂat, indicating no settling or nonspe-
ciﬁc binding of the magnetic nanotags (Supporting Information,
Figure S5). Similarly, when anti-Trop2 detection antibody was
added, it not only bound to the sensor immobilized with anti-
Trop2 capture antibody, but also bound to the sensor immobi-
lized with EGFR protein (Figure 3d). Anti-CEA antibody,
however, again exhibited no cross-reaction (refer to Supporting
Information,FigureS6fordemonstrationofcontrolexperiments
that reveal no cross-reactivity). This is the ﬁrst demonstration
of a technology capable of rapidly isolating individual cross-
reactive binding events in a multiplex manner. The technology is
potentially high-throughput because the number of nanosensors
on a single chip is highly scalable.
In the literature, both monoclonal and polyclonal antibodies
have been shown to cross-react with epitopes on nontarget anti-
gens.Infact,physicianshaveutilizedcross-reactiveantibodiesfor
the diagnosis of medical disease. The Venereal Disease Research
Laboratory (VDRL) test, for example, is a very common blood
testforsyphilisthatdetectsnonspeciﬁcantibodyinhumanserum
that reacts with beef cardiolipin.
21 Such a large incidence of
antibody cross-reactivity is clearly worrisome, as the aberrant
binding events that have been reported most likely just scratch
the surface of the problem. Even more problematic is the use of
antibodies with unknown cross-reactivity properties. With the
Figure 3. (a) Schematic representation of anti-EGFR antibody binding over sensors immobilized with EpCAM protein, EGFR protein, and Trop2
proteintoillustrateonepossiblemechanismofantibody-crossreactivity.(b)Twentyuniquecaptureantibodieswereselectivelyimmobilizedonunique
sensors in replicas of 3-7. All 20 proteins were incubated at high concentration (approximately 10 ng/mL). After washing, magnetic nanotags were
addedfollowedbyanti-EGFRantibody.Theautoassemblyassaywasrunfor5minresultinginsignalovertheEGFRsensors,Trop2sensorsandEpCAM
sensors. (c) Autoassembly immunoassay where anti-EGFR detection antibody was introduced ﬁrst and exhibited cross-reactivity with anti-EpCAM
immobilized sensor. Upon addition of anti-CEA detection antibody and anti-EpCAM detection antibody, no additional cross reactivity was observed.
(d) Autoassembly immunoassay where anti-Trop2 detection antibody was introduced ﬁrst and exhibited cross-reactivity with anti-EGFR immobilized
sensor. Addition of anti-CEA detection antibody at the end, however, exhibited no cross reactivity.2583 dx.doi.org/10.1021/nl1026056 |Nano Lett. 2011, 11, 2579–2583
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drive to increase protein microarray density, identifying such
aberrant binding events is of paramount importance, and im-
plementing easy-to-use methods to do so must become standard
practice. However, no standardized methods currently exist.
Our unique approach has the ability address this problem and
dramatically improve the ﬁdelity of the protein microarray in a
simple, rapid and potentially high-throughput fashion. This
technologycanbeinstrumentalinhelpingtheproteinmicroarray
deliver on its vast promise.
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